News CMS aims for broader GLP-1 access via federal programmes CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.
News Andexxa reaches the end of the line in the US AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.
News DBV gets peanut allergy therapy programme back on track Shares in DBV have shot up on phase 3 results that set up a US filing for its peanut allergy therapy. which could plug a looming hole in the market.
News CDC signs off on advice ending universal hepatitis B jabs Overturning decades of advice, the CDC has said it no longer recommends that all US newborns receive a hepatitis B vaccine.
News Prof Jonathan Benger named as NICE's new CEO Prof Jonathan Benger will take over from Dr Sam Roberts as CEO of UK reimbursement authority NICE later this week, at a critical time for the agency.
News Kyverna rises on stiff person syndrome data Kyverna hopes to file CAR-T therapy miv-cell for approval as the first therapy for stiff person syndrome, a rare and debilitating autoimmune disease.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.